[Antiulcer activity of furoxanopyrimidine derivatives].

A series of four new furoxanopyrimidine derivatives was synthesized and studied with respect to antiulcerous, antisecretory, and antibacterial activity. Two compounds exhibit antiulcerous effect not accompanied (in contrast to the well-known H2 receptor blockers, quiditene, and other antiulcerous drugs) by inhibition of gastric acid secretion. No one of the studied compounds exhibited antibacterial activity in the tests with Helicobacter pylori.

[An experimental study of the antisecretory and antiulcer activities of kviditen].

Quiditene-(qunuclidyl-3)-di-(thyenel-2)carbinole hydrochloride was studied by using various experimental models. The agent was compared with H2-blockers. When gastrically used, quiditene in doses of 5-50 mg/kg dose-dependently decreased gastric acid secretion and prevented acute gastric mucosal lesions.

[Selective inhibition of type A monoamine oxidase by pyrazidol].

Effect of a new antidepressant pyrazidol (1,10-trimethylene-8-methyl-1,2,3,4-tetrahydropyrazino /1,2-/ indole) on the liver and brain MAO activity of rats was studied in experiments in vivo and in vitro. Pyrazidol selectively blocks type A MAO (the substrates serotonin and noradrenaline) and does not virtually affect or has a far less action on type B MAO (the substrate 2-phenylethylamine).